jan 1, 2004 - FDA approves first "anti-angiogenic" drug, bevacizumab

Description:

Bavacizumab is the first of a new generation of targeted drugs that attacked cancer by blocking blood flow to the tumors.

Added to timeline:

16 Nov 2018

0

0

251

Cancer Dates

Date: